Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies

• Discussion of the role of immunomodulatory agents to reduce the cytokine storm in severe cases of COVID-19. • Potential immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine, hydroxychloroquine and tocilizumab) are discussed. • Other immunomodulatory agents with good saf...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhao, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. and International Society of Chemotherapy. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161506/
https://www.ncbi.nlm.nih.gov/pubmed/32305588
http://dx.doi.org/10.1016/j.ijantimicag.2020.105982
_version_ 1783522965055340544
author Zhao, Ming
author_facet Zhao, Ming
author_sort Zhao, Ming
collection PubMed
description • Discussion of the role of immunomodulatory agents to reduce the cytokine storm in severe cases of COVID-19. • Potential immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine, hydroxychloroquine and tocilizumab) are discussed. • Other immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19.
format Online
Article
Text
id pubmed-7161506
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V. and International Society of Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-71615062020-04-16 Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies Zhao, Ming Int J Antimicrob Agents Article • Discussion of the role of immunomodulatory agents to reduce the cytokine storm in severe cases of COVID-19. • Potential immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine, hydroxychloroquine and tocilizumab) are discussed. • Other immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19. Elsevier B.V. and International Society of Chemotherapy. 2020-06 2020-04-16 /pmc/articles/PMC7161506/ /pubmed/32305588 http://dx.doi.org/10.1016/j.ijantimicag.2020.105982 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Zhao, Ming
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
title Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
title_full Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
title_fullStr Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
title_full_unstemmed Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
title_short Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies
title_sort cytokine storm and immunomodulatory therapy in covid-19: role of chloroquine and anti-il-6 monoclonal antibodies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161506/
https://www.ncbi.nlm.nih.gov/pubmed/32305588
http://dx.doi.org/10.1016/j.ijantimicag.2020.105982
work_keys_str_mv AT zhaoming cytokinestormandimmunomodulatorytherapyincovid19roleofchloroquineandantiil6monoclonalantibodies

Ejemplares similares